Spero Therapeutics, Inc. Payments of Derivative Issuance Costs
Spero Therapeutics, Inc. (SPRO) reported Payments of Derivative Issuance Costs of $908.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDerivativeIssuanceCosts · last filed 2019-03-14
- Spero Therapeutics, Inc. payments of derivative issuance costs for fiscal 2016 was $908.00K.
| Period end | Payments of Derivative Issuance Costs 12 month |
|---|---|
| 2016-12-31 | $908.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |